Andera Partners Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001757283

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 7 positions · Total reported value $175.70M · Top-10 concentration 100.0% · Updated 2026-10-17

Last updated: 2026-10-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 0 new · 1 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Andera Partners disclosed 7 equity positions with a combined reported value of $175.70M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were KMTS ($77.19M), MLYS ($40.00M), AVLN ($26.49M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Andera Partners opened 0 new positions, trimmed 1 and fully exited 1, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 88% of names.

Of the 1 positions fully exited versus the prior quarter, the largest were ABVX ($10.41M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • ABVX ABIVAX SA · prev qtr: $10.41M

Insider Transactions (Form 4)

Latest Andera Partners buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Andera Partners files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 7 positions worth $175.70M in total. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).

Portfolio Structure

  • 7 positions · $175.70M reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: KMTS (KESTRA MEDICAL TECHNOLOGIES) at 43.9%
  • Average position size: $25.10M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 1 reduced, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a conservative stance in Q3 2026, with a focus on holding positions rather than making significant changes. The lack of new investments suggests a defensive strategy amidst market uncertainty or a preference for the current holdings. 2. Key Moves: - No additions: The fund did not add any new positions, indicating a preference for the existing portfolio or a cautious approach to new opportunities. - Reduction in EVOMMUNE INC (EVMN): A significant reduction of 93.0% in shares from 1,391,990 to 97,362 suggests a reevaluation of EVOMMUNE INC's potential and a decision to scale back exposure. 3. Portfolio Structure: - Passive vs. Active: The fund is passive in nature, as it held positions steady and made no new investments. - Sector Bias: The portfolio is heavily biased towards the Health Care sector, which accounts for over 90% of the total value. - Risk Appetite: The risk appetite is moderate to low, as indicated by the conservative stance and the reduction in a single position. 4. Per-Holding One-Liner: - KMTS (KESTRA MED TECHNOLOGIE F): Kestra Med Technology, a company in the medical technology sector. - MLYS (MINERALYS THERAPEUTICS INC): Mineralys Therapeutics, a biotechnology company focusing on novel therapies. - AVLN (AVALYN PHARMA INC): Avalyn Pharma, a pharmaceutical company specializing in drug development. - AGMB (AGOMAB THERAPEUTICS NV): Agomab Therapeutics, a biopharmaceutical company developing therapies. - IVA (INVENTIVA SA ADS): Inventiva, a biopharmaceutical company focused on metabolic diseases. - EVMN (EVOMMUNE INC): Unverified - EVOMMUNE INC is likely a biotechnology or pharmaceutical company, but the specific business is not confirmed. - NYXH (NYXOAH S A): Nyxoah, a medical device company specializing in treatments for sleep-disordered breathing. 5. One-Sentence Style Summary: Andera Partners maintained a passive, defensive stance in Q3 2026, focusing on a well-diversified health care portfolio with a significant sector bias towards biotechnology and pharmaceuticals, while reducing exposure to one company.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.73M $77.19M 43.94%
43.94%
Hold
2 1.59M $40.00M 22.77%
22.77%
Hold
3 929.82K $26.49M 15.08%
15.08%
Hold
4 1.54M $17.08M 9.72%
9.72%
Hold
5 3.63M $13.41M 7.63%
7.63%
Hold
6 97.36K $804.21K 0.46%
0.46%
Reduce
7 522.06K $720.44K 0.41%
0.41%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 88% R 100% F1 93% (modelled on 2026-Q2; 7/10 hit)

Historical Backtest (2 quarters)

Avg precision 94% · recall 94% · F1 93% · avg rank error 1.4 · Top-10 turnover 4%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 100% 88% 93% KMTS · EVMN · MLYS · AGMB · IVA · ABVX · NYXH KMTS · MLYS · AVLN · AGMB · EVMN · IVA · ABVX · NYXH
2026-Q3 ★ 88% 100% 93% KMTS · MLYS · AVLN · AGMB · EVMN · IVA · ABVX · NYXH KMTS · MLYS · AVLN · AGMB · IVA · EVMN · NYXH

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Andera Partners buy in 2026-Q3?

In its 2026-Q3 13F filing, Andera Partners reported 7 equity positions worth $175.70M in aggregate; its largest disclosed positions were KMTS ($77.19M), MLYS ($40.00M), AVLN ($26.49M).

How large is Andera Partners's portfolio?

Andera Partners reported $175.70M of long equity holdings across 7 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Andera Partners's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/andera-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →